Form 4: Repare Therapeutics Director Sells Shares in Acquisition

A director of Repare Therapeutics Inc. reported the disposition of common shares and stock options as part of an Arrangement Agreement for the company's acquisition.

Summary

• Director Carol Schafer disposed of 8,000 common shares of Repare Therapeutics Inc. on January 28, 2026.
• Additionally, 37,941 stock options with an exercise price of $2.062 were disposed of on the same date.
• These transactions are pursuant to an Arrangement Agreement dated November 14, 2025, involving Repare Therapeutics Inc. and XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
• Common shareholders are receiving $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share.
• Stock options were cancelled in exchange for $2.20 less the applicable exercise price, plus one CVR per share underlying such option.
• Following these transactions, Carol Schafer's beneficial ownership of both common shares and derivative securities is 0.

Sentiment

Score: 7

Explanation: The filing reports the expected disposition of shares and options due to an acquisition, which provides a defined return for shareholders through cash and CVRs. While it marks the end of the company's independent public trading, the terms appear to be a structured exit.

Positives

• The acquisition provides a defined exit strategy for Repare Therapeutics Inc. shareholders.
• Shareholders receive a cash component of $2.20 per share, offering immediate liquidity.
• The inclusion of a contingent value right (CVR) offers potential future upside based on undisclosed milestones or performance.

Negatives

• Repare Therapeutics Inc. will cease to be an independent publicly traded company, removing its shares from public markets.
• The specific value and terms of the contingent value right (CVR) are not detailed, introducing uncertainty regarding its ultimate worth.

Risks

• The value of the contingent value right (CVR) is inherently uncertain and dependent on future events or performance, which are not specified in this filing.
• There is a risk that the acquisition, while reported as proceeding, could still face unforeseen hurdles or conditions that might delay or alter its terms, though this filing indicates execution.

Future Outlook

Repare Therapeutics Inc. is transitioning from an independent public entity to an acquired company. Its shares and options are being exchanged for cash and contingent value rights, indicating the conclusion of its public trading status and a shift in ownership and operational control.

Industry Context

This transaction reflects a common trend in the biotechnology and pharmaceutical sectors where smaller, often clinical-stage, companies are acquired by larger entities. The use of contingent value rights (CVRs) is a frequent mechanism in these acquisitions to bridge valuation gaps, particularly when the target company's assets have future milestones or uncertain outcomes.

Comparison to Industry Standards

• The use of a Contingent Value Right (CVR) in an acquisition is a standard practice in the biotechnology and pharmaceutical industries, often employed when the target company possesses early-stage assets or uncertain future milestones. This structure has been observed in various industry acquisitions, such as those involving companies with drug candidates awaiting regulatory approval or clinical trial results.
• The cash consideration of $2.20 per share would typically be evaluated against the company's pre-announcement trading prices, analyst consensus targets, and comparable transactions in the sector to determine the premium or discount offered to shareholders. Without this external market data, a direct benchmark of the specific value is not feasible from the filing alone.

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive $2.20 cash per share and one CVR per share, providing a defined return and potential future upside.
• Employees: While not directly addressed, acquisitions often lead to integration processes that can impact employee roles and structures.
• Management/Directors: Director Carol Schafer's beneficial ownership in the company is being liquidated as part of the acquisition.

Next Steps

• Completion of the acquisition of Repare Therapeutics Inc. by XenoTherapeutics, Inc. and its affiliates.
• Realization of value from the Contingent Value Rights (CVRs) based on their specific terms and the achievement of underlying milestones (not detailed in this filing).

Key Dates

Recommendation

The filing details the final stages of an announced acquisition, where the terms for shareholders are already set. For existing shareholders, a 'hold' recommendation is appropriate to receive the agreed-upon consideration (cash plus CVR) upon the deal's closing. There is no further upside from the company's independent operations, and the primary risk is the deal failing, which is not indicated. New investors would likely find limited opportunity as shares would trade near the acquisition price.

Keywords

Repare Therapeutics, RPTX, XenoTherapeutics, XOMA Royalty Corporation, Acquisition, Merger, Form 4, Insider Transaction, Director, Common Shares, Stock Options, Contingent Value Right, CVR, Corporate Governance